| Identification | Back Directory | [Name]
11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate | [CAS]
75451-07-9 | [Synonyms]
AZ-1355
(NSC 364889
11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate
Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-, ethyl ester | [Molecular Formula]
C17H17NO4 | [MDL Number]
MFCD31382162 | [MOL File]
75451-07-9.mol | [Molecular Weight]
299.32 |
| Hazard Information | Back Directory | [Uses]
AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro. | [in vivo]
AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rat. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice[1]. | [IC 50]
TXA2/TP; Prostaglandin I2 | [storage]
Store at -20°C | [References]
[1] Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40(3-4):263-71. DOI:10.1016/0021-9150(81)90136-2
[2] Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40(3-4):263-71. |
|
|